SAN
DIEGO, Aug. 29, 2022 /PRNewswire/ -- Cue Health
Inc. (Nasdaq: HLTH), a healthcare technology company that puts
diagnostic information at the center of care, today announced the
nationwide launch of Cue Care™, its same-day, at-home,
test-to-treatment solution. Patients in any of the 50 states who
test positive using Cue's COVID-19 tests can now use the Cue Health
App to:
- Consult virtually and on-demand with a healthcare professional
about their test result;
- Obtain an e-prescription - if medically indicated - for a
medication to treat the virus; and
- Get the medication delivered - usually within hours* -
conveniently and safely at home or the medication will be made
available for pickup at their local pharmacy.
Within a few weeks, Cue Health anticipates expanding this new
service to patients who test positive on any COVID-19 test,
including at-home antigen tests. The Cue Care antiviral delivery
service costs between $79 and
$99 and includes a televisit with a
healthcare professional and delivery of a medication, the cost of
which is currently covered by the U.S. Department of Health and
Human Services (HHS). According to HHS, early COVID-19 treatment
can help improve patient outcomes, reduce hospitalization, and even
save lives.
"Early diagnosis and treatment have shown to lead to better
health outcomes, which is why we're proud to deliver timely testing
and treatment all within the Cue Health App," said Ayub Khattak, Chairman and CEO of Cue Health.
"Cue Care meets the need today for convenient delivery of COVID-19
treatment, and this capability will support our expanding pipeline
of future diagnostics tests."
Current and future testing capabilities
While Cue Care is for COVID-19 patients today, it
is expected to apply to a wide range of diagnostic tests in
Cue's pipeline, particularly those for which specific treatments
are available. For example, if an individual tests positive for
flu, they will be able to use Cue Care to connect with a healthcare
professional and, if eligible, get an antiviral for flu delivered
to them on the same day, all within the Cue Health App. Cue Care is
expected to handle other respiratory infections, such as strep
throat and respiratory syncytial virus (RSV), as well as sexually
transmitted infections, such as chlamydia and gonorrhea.
Cue has the most accurate at-home COVID-19 test**,
delivering results in 20 minutes to connected mobile devices. It
detects all known COVID-19 variants of concern in people with or
without symptoms. Cue is used in homes, in point-of-care settings,
and by world-class organizations across the country, including
Johns Hopkins Medicine, Mayo Clinic, Google, the National
Basketball Association, and Major League Baseball, among many
others.
* Antiviral medications prescribed by independent healthcare
professionals through Cue Care are subject to availability and
patient eligibility. Cue Health Inc. is not affiliated with any
pharmaceutical manufacturer.
** #1 accuracy claim based on comparison of clinical study
results submitted to the U.S. Food and Drug Administration (FDA)
for Emergency Use Authorization for Cue and other molecular home
tests.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easier for individuals to access health information
and places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organization, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements". The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including those related
to the expected future diagnostic test menu and the factors
discussed in the "Risk Factors" section of Cue's Annual Report on
Form 10-K for the year ended December 31,
2021 and Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022 filed with the SEC on
August 10, 2022. Any forward-looking
statements contained in this press release are based on the current
expectations of Cue's management team and speak only as of the date
hereof, and Cue specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Cue's COVID-19 tests have not been FDA cleared or approved; but
have been authorized by FDA and under an Emergency Use
Authorization (EUA). These products have been authorized only for
the detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens. The emergency use of these products is only
authorized for the duration of the declaration that circumstances
exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-launches-cue-care-nationwide-to-provide-same-day-at-home-test-to-treatment-service-for-covid-19-301613695.html
SOURCE Cue Health Inc.